Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases
Rhea-AI Summary
Jaguar Health (NASDAQ:JAGX)/b) announced that founder, president and CEO Lisa Conte will present virtually at the on Wednesday, June 24, 2026 at 1:00 PM Eastern. Investors can register online, and a replay of the webcast will be available after the conference.
Positive
- None.
Negative
- None.
News Market Reaction – JAGX
In the Jun 12 session, JAGX declined 4.44%, reflecting a moderate negative market reaction. Argus tracked a trough of -11.2% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 08 | Annual meeting results | Positive | -4.0% | Stockholders approved all proposals and CEO flagged upcoming conference presentation. |
| May 28 | Pipeline development | Positive | +3.1% | Ethnobotanical research and data supported crofelemer development for rare GI disorders. |
| May 27 | Nasdaq compliance, update | Positive | +2.6% | Regained Nasdaq bid-price compliance and highlighted major revenue growth and NDA plans. |
| May 20 | Quarterly financials | Positive | -5.5% | Reported strong Q1 2026 revenue and operational improvement tied to licensing deal. |
| May 20 | Webcast & conference | Neutral | +2.8% | Announced Q1 webcast and investor conference presentation with replay availability. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent JAGX news has produced mixed reactions, with positive operational or financial updates sometimes met by selling, particularly around earnings, while regulatory and corporate progress has more often aligned with modest price gains.
Over the last month, Jaguar Health has combined financial turnaround with active investor outreach and regulatory milestones. Q1 2026 results on May 20 showed sharp revenue growth yet saw a -5.45% reaction, while subsequent updates on regaining Nasdaq compliance and advancing crofelemer for rare intestinal failure drew positive moves between 2.57% and 3.13%. Stockholder meeting approvals on June 8 coincided with a -4.03% move. Today’s event-focused announcement continues a pattern of frequent conference and webcast visibility tied to the crofelemer program.
Key Terms
microvillus inclusion disease medical
short bowel syndrome medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Click here to register for event
To access the replay of the June 10, 2026 presentation by Lisa Conte, Jaguar's founder, president & CEO, at the Emerging Growth Conference, click here
Reminder: Two crofelemer presentations in pediatric intestinal failure patients with microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) to be conducted at June 24-27, 2026 Annual European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) Meeting
SAN FRANCISCO, CA / ACCESS Newswire / June 12, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Wednesday, June 24, 2026 at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com.
Participation Instructions for Jaguar's Presentation at the Life Sciences Virtual Investor Forum
When: Wednesday, June 24, 2026 at 1:00 PM Eastern
Registration link for conference: Click Here
Replay: A replay of the webcast will be available following the conclusion of the conference.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. ("Jaguar") develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal ("GI") disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Jaguar management will present at the June 2026 conference listed above, and the expectation that two crofelemer-related presentations in pediatric intestinal failure patients with MVID and SBS-IF will be made at the 58th ESPGHAN Annual Meeting in June 2026. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
hello@jaguar.health
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire